Myriad Genetics Inc (MYGN)

20.47
NASDAQ : Services
Prev Close 20.47
Day Low/High 0.00 / 0.00
52 Wk Low/High 15.15 / 35.35
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 68.12M
Market Cap 1.40B
EPS 1.80
P/E Ratio 45.82
Div & Yield N.A. (N.A)

Latest News

Myriad Genetics To Present Results From Four Studies At The American Urological Association 2017 Annual Meeting

Myriad Genetics To Present Results From Four Studies At The American Urological Association 2017 Annual Meeting

Featured Study Will Show Power of the Prolaris Test to Predict 10-Year Risk of Metastases in Men Treated for Prostate Cancer

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.

Study Finds Wide Gap In Quality Of BRCA1/2 Variant Classification Between Myriad Genetics And A Common Public Database

Study Finds Wide Gap In Quality Of BRCA1/2 Variant Classification Between Myriad Genetics And A Common Public Database

26 Percent Discordance Rates Observed in Public Databases

Myriad Genetics And BeiGene Sign Agreement To Develop Companion Diagnostics For Use With BeiGene's Novel PARP Inhibitor, BGB-290

Myriad Genetics And BeiGene Sign Agreement To Develop Companion Diagnostics For Use With BeiGene's Novel PARP Inhibitor, BGB-290

Collaboration Will Evaluate Myriad's myChoice® HRD and BRACAnalysis CDx® Tests

Pivotal Study Results For Myriad's MyPath® Melanoma Test Highlighted In Two Additional Scientific Publications

Pivotal Study Results For Myriad's MyPath® Melanoma Test Highlighted In Two Additional Scientific Publications

The Company Will Seek Reimbursement from Medicare and Private Payers

Myriad Genetics Announces Five Scientific Presentations At The 2017 American College Of Medical Genetics Annual Clinical Genetics Meeting

Myriad Genetics Announces Five Scientific Presentations At The 2017 American College Of Medical Genetics Annual Clinical Genetics Meeting

New Data Will Highlight Advances in Genetic Variant Classification for Hereditary Cancers

Myriad Genetics Launches The EndoPredict® Test In The United States For Patients With Breast Cancer

Myriad Genetics Launches The EndoPredict® Test In The United States For Patients With Breast Cancer

Second-Generation Test Provides More Accurate 10-Year Recurrence Risk for Patients Diagnosed with ER+ HER2- Early-Stage Breast Cancer

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABCO, AEGN, AVGO, GKOS, GPT, GTN, MYGN, SINO, THRM Downgrades: AN, CODI, PRGX, TAIT, TREC Initiations: BMCH Read on to get TheStreet Quant Ratings' detailed report:

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings For Payers In New Study Published In Clinical Therapeutics

GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings For Payers In New Study Published In Clinical Therapeutics

Economic Utility Study Showed Annual Cost Savings of $3,988 per Member

Myriad's Prolaris® Test Significantly Improves The Risk Classification For One Third Of Men Diagnosed With Localized Prostate Cancer

Myriad's Prolaris® Test Significantly Improves The Risk Classification For One Third Of Men Diagnosed With Localized Prostate Cancer

New Data from 16,000 Patient Study to Be Presented at 2017 ASCO GU

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments

Cramer points to Gilead's pipeline for its problems.

Noteworthy Friday Option Activity: MYGN, SEMG, BOBE

Noteworthy Friday Option Activity: MYGN, SEMG, BOBE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Myriad Genetics, Inc. , where a total volume of 52,093 contracts has been traded thus far today, a contract volume which is representative of approximately 5.2 million underlying shares (given that every 1 contract represents 100 underlying shares).

The EndoPredict® Test Receives Positive Coverage Decisions From Multiple Blue Cross Blue Shield Affiliate Plans

The EndoPredict® Test Receives Positive Coverage Decisions From Multiple Blue Cross Blue Shield Affiliate Plans

Coverage Decisions Expand Access to More Than 32 Million Patients

EndoPredict® Reviewed By Blue Cross Blue Shield Association's Evidence Street

EndoPredict® Reviewed By Blue Cross Blue Shield Association's Evidence Street

The Level of Evidence for EndoPredict Consistent with that of First-Generation Test

Positive Clinical Utility Results Of Crescendo's Vectra® DA Test For Rheumatoid Arthritis Published In The Journal Arthritis & Rheumatology

Positive Clinical Utility Results Of Crescendo's Vectra® DA Test For Rheumatoid Arthritis Published In The Journal Arthritis & Rheumatology

Vectra DA Test Guides Treatment for Rheumatoid Arthritis Patients that are Methotrexate-Incomplete Responders

Myriad Genetics Will Present Results From Six Breast Cancer Studies At SABCS

Myriad Genetics Will Present Results From Six Breast Cancer Studies At SABCS

New Data on EndoPredict®, myRisk™ Hereditary Cancer and myChoice® HRD

Crescendo Bioscience Announces Four Studies With Vectra® DA Will Be Presented At The American College Of Rheumatology 2016 Annual Meeting

Crescendo Bioscience Announces Four Studies With Vectra® DA Will Be Presented At The American College Of Rheumatology 2016 Annual Meeting

Studies Advance the Knowledge of Vectra DA Utility for Clinicians and Patients with RA